Bridgebio Pharma Share Price (NASDAQ: BBIO)

Market is closed - opens 7 PM IST, 04 Aug 2025

$47.38

▲

0.11

(0.23%)

Last updated on 02 Aug 2025, 01:29 AM IST

$₹

Check the interactive Bridgebio Pharma Stock chart to analyse performance

Bridgebio Pharma stock performance

as on 02 Aug 2025, 01:29 AM IST

Today's Low: $46.55
Today's High: $47.99
$47.38
1.75%
Downside
Day's Volatility :2.99%
Upside
1.26%
52 Weeks Low: $21.72
52 Weeks High: $48.68
$47.38
54.16%
Downside
52 Weeks Volatility :55.38%
Upside
2.67%

Bridgebio Pharma Stock Returns

Period	Bridgebio Pharma Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	23.97%	-5.9%	0.0%
6 Months	52.69%	-11.2%	0.0%
1 Year	80.98%	-13.5%	0.0%
3 Years	496.73%	-0.4%	-6.0%

Bridgebio Pharma Inc Key Stats

Check Bridgebio Pharma key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$47.27
Open	$46.75
Today's High	$47.985
Today's Low	$46.55
Market Capitalization	$9.0B
Today's Volume	$2.2M
52 Week High	$48.6809
52 Week Low	$21.72
Revenue TTM	$127.4M
EBITDA	$-662.6M
Earnings Per Share (EPS)	$-3.56
Profit Margin	0.0%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-1789.67%

Stock Returns calculator for Bridgebio Pharma Stock including INR - Dollar returns

The Bridgebio Pharma stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Bridgebio Pharma investment value today

Current value as on today

₹1,85,391

Returns

₹85,391

(+85.39%)

Returns from Bridgebio Pharma Stock

₹80,978 (+80.98%)

Dollar Returns*

₹4,413 (+4.41%)

Indian investors sentiment towards Bridgebio Pharma Stock

-33%

Period: Jul 2, 2025 to Aug 1, 2025. Change in 30 Days versus previous period

Search interest for Bridgebio Pharma Stock from India on INDmoney has decreased by -33% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Bridgebio Pharma Inc

Name
Holdings %
Name
Holdings %
Viking Global Investors LP
11.62%
Kohlberg Kravis Roberts & Co LP
10.14%
Vanguard Group Inc
7.85%
BlackRock Inc
7.03%
HHG PLC
3.78%
Aisling Capital Management LP
3.20%

Analyst Recommendation on Bridgebio Pharma Stock

Rating

Trend

Buy

85%Buy

15%Hold

0%Sell

Based on 20 Wall street analysts offering stock ratings for Bridgebio Pharma(by analysts ranked 0 to 5 stars)

Bridgebio Pharma Share Price Target

What analysts predicted

Upside of 29.71%

Target:

$61.45

Current:

$47.38

Bridgebio Pharma share price target is $61.45, a slight Upside of 29.71% compared to current price of $47.38 as per analysts' prediction.

Bridgebio Pharma Stock Insights

Price Movement
In the last 6 months, BBIO stock has moved up by 38.0%
Increasing Revenue
Revenue is up for the last 4 quarters, 2.16M → 116.63M (in $), with an average increase of 56.4% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -265.05M → -167.42M (in $), with an average increase of 58.3% per quarter
BBIO vs ONC (1 yr)
In the last 1 year, Beone Medicines Ltd has given 84.2% return, outperforming this stock by 3.8%
Price to Sales
ForBBIO every $1 of sales, investors are willing to pay $70.3, whereas for Beone Medicines Ltd, the investors are paying $7.6 for every $1 of sales.

Bridgebio Pharma Inc Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$40.6M	-
Net Income	$-260.4M	↑ 99.19%
Net Profit Margin	-642.1%	-

	FY20	Y/Y Change
Revenue	$8.2M	↓ 79.66%
Net Income	$-483.9M	↑ 85.81%
Net Profit Margin	-5.9K%	↓ 5224.37%

	FY21	Y/Y Change
Revenue	$69.7M	↑ 745.14%
Net Income	$-639.3M	↑ 32.11%
Net Profit Margin	-917.0%	↑ 4949.47%

	FY22	Y/Y Change
Revenue	$77.6M	↑ 11.38%
Net Income	$-494.0M	↓ 22.73%
Net Profit Margin	-636.16%	↑ 280.84%

	FY23	Y/Y Change
Revenue	$9.3M	↓ 88.02%
Net Income	$-643.2M	↑ 30.21%
Net Profit Margin	-6.9K%	↓ 6277.76%

	FY24	Y/Y Change
Revenue	$221.9M	↑ 2285.27%
Net Income	$-535.8M	↓ 16.7%
Net Profit Margin	-241.44%	↑ 6672.48%

Q4 FY23

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

	Q4 FY23	Q/Q Change
Revenue	$1.7M	↓ 57.35%
Net Income	$-168.1M	↓ 5.0%
Net Profit Margin	-9.6K%	↓ 5309.44%

	Q1 FY24	Q/Q Change
Revenue	$211.1M	↑ 11998.57%
Net Income	$-35.2M	↓ 79.06%
Net Profit Margin	-16.68%	↑ 9619.31%

	Q2 FY24	Q/Q Change
Revenue	$2.2M	↓ 98.97%
Net Income	$-73.5M	↑ 108.59%
Net Profit Margin	-3.4K%	↓ 3371.51%

	Q3 FY24	Q/Q Change
Revenue	$2.7M	↑ 26.01%
Net Income	$-162.0M	↑ 120.59%
Net Profit Margin	-5.9K%	↓ 2543.0%

	Q4 FY24	Q/Q Change
Revenue	$5.9M	↑ 115.3%
Net Income	$-265.1M	↑ 63.57%
Net Profit Margin	-4.5K%	↑ 1425.07%

	Q1 FY25	Q/Q Change
Revenue	$116.6M	↑ 1882.88%
Net Income	$-167.4M	↓ 36.83%
Net Profit Margin	-143.55%	↑ 4362.57%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$38.1M	-

	FY20	Y/Y Change
Profit	$5.2M	↓ 86.44%

	FY21	Y/Y Change
Profit	$66.6M	↑ 1190.49%

	FY22	Y/Y Change
Profit	$74.2M	↑ 11.43%

	FY23	Y/Y Change
Profit	$6.9M	↓ 90.76%

	FY24	Y/Y Change
Profit	$218.0M	↑ 3079.58%

Q4 FY23

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

	Q4 FY23	Q/Q Change
Profit	$1.1M	↓ 67.16%

	Q1 FY24	Q/Q Change
Profit	$209.2M	↑ 18141.15%

	Q2 FY24	Q/Q Change
Profit	$1.6M	↓ 99.25%

	Q3 FY24	Q/Q Change
Profit	$2.1M	↑ 35.92%

	Q4 FY24	Q/Q Change
Profit	$3.8M	↑ 77.98%

	Q1 FY25	Q/Q Change
Profit	$116.0M	↑ 2954.98%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$-253.6M	↑ 85.58%
Investing Cash Flow	$-217.3M	↑ 932.77%
Financing Cash Flow	$398.8M	↓ 20.49%

	FY20	Y/Y Change
Operating Cash Flow	$-399.7M	↑ 57.62%
Investing Cash Flow	$-53.0M	↓ 75.61%
Financing Cash Flow	$447.2M	↑ 12.14%

	FY21	Y/Y Change
Operating Cash Flow	$-497.9M	↑ 24.57%
Investing Cash Flow	$-200.8M	↑ 278.97%
Financing Cash Flow	$736.4M	↑ 64.68%

	FY22	Y/Y Change
Operating Cash Flow	$-419.5M	↓ 15.75%
Investing Cash Flow	$453.1M	↓ 325.64%
Financing Cash Flow	$-13.1M	↓ 101.78%

	FY23	Y/Y Change
Operating Cash Flow	$-527.7M	↑ 25.8%
Investing Cash Flow	$54.0M	↓ 88.08%
Financing Cash Flow	$451.5M	↓ 3537.91%

	FY24	Y/Y Change
Operating Cash Flow	$-520.7M	↓ 1.33%
Investing Cash Flow	$60.8M	↑ 12.49%
Financing Cash Flow	$748.5M	↑ 65.76%

Q4 FY23

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

	Q4 FY23	Q/Q Change
Operating Cash Flow	$-124.8M	↓ 14.05%
Investing Cash Flow	$-66.0K	↓ 100.18%
Financing Cash Flow	$-4.5M	↓ 101.47%

	Q1 FY24	Q/Q Change
Operating Cash Flow	$-219.5M	↑ 75.88%
Investing Cash Flow	$22.8M	↓ 34574.24%
Financing Cash Flow	$279.5M	↓ 6280.59%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$74.7M	↓ 134.03%
Investing Cash Flow	$3.0M	↓ 86.64%
Financing Cash Flow	$-5.7M	↓ 102.05%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$-180.6M	↓ 341.71%
Investing Cash Flow	$38.2M	↑ 1157.85%
Financing Cash Flow	$707.0K	↓ 112.34%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$-195.3M	↑ 8.17%
Investing Cash Flow	$-3.2M	↓ 108.47%
Financing Cash Flow	$473.9M	↑ 66934.09%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$-199.2M	↑ 2.0%
Investing Cash Flow	$-1.6M	↓ 50.73%
Financing Cash Flow	$60.3M	↓ 87.27%

Bridgebio Pharma Technicals Summary

Sell

Neutral

Buy

Bridgebio Pharma is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Bridgebio Pharma Inc Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Bridgebio Pharma Inc	7.34%	52.69%	80.98%	496.73%	74.19%
Regeneron Pharmaceuticals, Inc.	-0.36%	-16.51%	-48.55%	-8.54%	-13.7%
Beone Medicines Ltd	22.47%	33.89%	83.22%	76.22%	34.92%
Vertex Pharmaceuticals Incorporated	-0.64%	-1.72%	-6.51%	68.08%	65.38%
Alnylam Pharmaceuticals, Inc.	18.03%	46.25%	47.6%	89.4%	163.65%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Bridgebio Pharma Inc	NA	NA	NA	-2.6	-17.9	-0.48	NA	-8.68
Regeneron Pharmaceuticals, Inc.	14.1	14.1	1.17	35.44	0.16	0.07	0.0	277.5
Beone Medicines Ltd	NA	NA	NA	1.18	-0.11	-0.03	NA	32.42
Vertex Pharmaceuticals Incorporated	32.84	NA	0.58	17.93	-0.06	0.12	NA	64.2
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	1.74	-15.01	-0.02	NA	0.89

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Bridgebio Pharma Inc	Buy	$9.0B	74.19%	NA	0.0%
Regeneron Pharmaceuticals, Inc.	Buy	$59.9B	-13.7%	14.1	31.94%
Beone Medicines Ltd	NA	$33.9B	34.92%	NA	-9.4%
Vertex Pharmaceuticals Incorporated	Buy	$120.5B	65.38%	32.84	-8.91%
Alnylam Pharmaceuticals, Inc.	Buy	$44.3B	163.65%	NA	-11.49%

Bridgebio Pharma Dividend announcements

Bridgebio Pharma Earnings
Bridgebio Pharma’s price-to-earnings ratio stands at None

About Bridgebio Pharma Inc

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; low-dose infigratinib, a treatment option for children living with hypochondroplasia, a skeletal dysplasia closely related to achondroplasia which is in Phase 2/3. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. The company has license and collaboration agreements with the Alexion Pharma International Operations Unlimited Company, Leland Stanford Junior University and Leidos Biomedical Research, Inc., and Novartis International Pharmaceutical Ltd. BridgeBio Pharma, Inc. was founded in 2015 and is headquartered in Palo Alto, California.

Organization	Bridgebio Pharma
Employees	725
CEO	Dr. Eric Michael David J.D., M.D., Ph.D.
Industry	Health Technology

Key Management of Bridgebio Pharma Inc

Name	Title
Dr. Neil Kumar Ph.D.	Co-Founder, CEO & Director
Dr. Thomas Trimarchi Ph.D.	CFO & President
Dr. Charles J. Homcy M.D.	Co-Founder, Chairman of Pharmaceuticals & Independent Lead Director
Dr. Frank P. McCormick Ph.D.	Co-Founder, Chairman of Oncology & Director
Ms. Maricel M. Apuli	Chief Accounting Officer
Dr. Uma Sinha Ph.D.	Chief Scientific Officer
Dr. Richard H. Scheller Ph.D.	Chairman of Research & Development
Mr. Eli M. Wallace Ph.D.	Chief Scientific Officer of Oncology
Dr. Eric Michael David J.D., M.D., Ph.D.	Chief Executive Officer of Gene Therapy
Mr. Matthew Outten CPC, MBA	Chief Commercial Officer

Important FAQs about investing in BBIO Stock from India :

How to invest in Bridgebio Pharma Stock (BBIO) from India?

It is very easy for Indian residents to invest directly in Bridgebio Pharma from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Bridgebio Pharma stock in both Indian Rupees (INR) and US Dollars (USD). Search for Bridgebio Pharma or BBIO on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Bridgebio Pharma or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Bridgebio Pharma shares which would translate to 0.018 fractional shares of Bridgebio Pharma as of today. Learn more about fractional investing.

Can Indians buy Bridgebio Pharma shares?

Yes, Indians can invest in the Bridgebio Pharma (BBIO) from India.

With INDmoney, you can buy Bridgebio Pharma at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Bridgebio Pharma at zero transaction cost.

How can I buy Bridgebio Pharma shares from India?

It is very easy to buy Bridgebio Pharma from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Bridgebio Pharma (BBIO) be purchased?

Yes, you can buy fractional shares of Bridgebio Pharma with INDmoney app.

What are the documents required to start investing in Bridgebio Pharma stocks?

To start investing in Bridgebio Pharma, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What is Bridgebio Pharma share price today?

Bridgebio Pharma share price today stands at $47.38, Open: $46.75 ; Previous Close: $47.27 ; High: $47.99 ; Low: $46.55 ; 52 Week High: $48.68 ; 52 Week Low: $21.72.

The stock opens at $46.75, after a closing price of $47.27. The stock reached a daily high of $47.99 and a low of $46.55, with a 52-week high of $48.68 and a 52-week low of $21.72.